Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. Among authors: pavel ab. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. Among authors: pavel ab. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation.
Song T, Pavel AB, Wen HC, Malik K, Estrada Y, Gonzalez J, Hashim PW, Nia JK, Baum D, Kimmel G, Singer GK, Krueger JG, Guttman-Yassky E. Song T, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13. doi: 10.1016/j.jaci.2018.06.029. Epub 2018 Jul 5. J Allergy Clin Immunol. 2018. PMID: 29981808 No abstract available.
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. Mikhaylov D, et al. Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11. Arch Dermatol Res. 2019. PMID: 30417279 Clinical Trial.
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.
Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, Wen HC, Xu H, Estrada YD, Peng X, Chen M, Shah N, Suarez-Farinas M, Pavel AB, Nograles K, Guttman-Yassky E. Simpson EL, et al. Among authors: pavel ab. J Invest Dermatol. 2019 May;139(5):1063-1072. doi: 10.1016/j.jid.2018.10.043. Epub 2018 Dec 5. J Invest Dermatol. 2019. PMID: 30528828 Free article. Clinical Trial.
Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases.
Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen HC, Kimmel GW, Kim HJ, Chima M, Lebwohl M, Krueger JG, Guttman-Yassky E. Czarnowicki T, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2019 Jun;143(6):2095-2107. doi: 10.1016/j.jaci.2018.11.031. Epub 2018 Dec 18. J Allergy Clin Immunol. 2019. PMID: 30576756
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.
Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G. Guttman-Yassky E, et al. Among authors: pavel ab. J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7. doi: 10.1016/j.jaci.2018.11.053. Epub 2019 Feb 6. J Allergy Clin Immunol. 2019. PMID: 30738171 Free article. Clinical Trial.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E. Bissonnette R, et al. Among authors: pavel ab. Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6. Br J Dermatol. 2019. PMID: 30919407 Free PMC article. Clinical Trial.
The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.
Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, Canter T, Puar N, Rangel SM, Malik K, Estrada Y, Krueger JG, Guttman-Yassky E, Paller AS. Brunner PM, et al. Among authors: pavel ab. J Am Acad Dermatol. 2019 Aug;81(2):510-519. doi: 10.1016/j.jaad.2019.04.036. Epub 2019 Apr 19. J Am Acad Dermatol. 2019. PMID: 31009665
Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals.
Del Duca E, Pavel AB, Dubin C, Song T, Wallace EB, Peng X, Estrada YD, Xu H, Maari C, Jack C, St-Cyr Proulx E, Krueger JG, Bissonnette R, Guttman-Yassky E. Del Duca E, et al. Among authors: pavel ab. J Invest Dermatol. 2019 Oct;139(10):2228-2232.e10. doi: 10.1016/j.jid.2019.04.008. Epub 2019 May 3. J Invest Dermatol. 2019. PMID: 31059695 Free article. No abstract available.
83 results